Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Latest predictions
€110.00
20.10.20
buy
Your prediction

PerkinElmer Inc. Stock

The price for the PerkinElmer Inc. stock decreased slightly today. Compared to yesterday there is a change of -€1.000 (-0.830%).
With 0 Sell predictions and 1 Buy predictions the community sentiment towards the PerkinElmer Inc. stock is not clear.
On the other hand, the target price of €110.00 is below the current price of €120.00 for PerkinElmer Inc., so the potential is actually -8.333%.
So far the community has only identified positive things for PerkinElmer Inc. stock. The most positive votes were given for criterium "EBIT growth".

Pros and Cons of PerkinElmer Inc. in the next few years

Pros
1
EBIT growth >5% per year expected
1
Could be worthwhile Investment >10% per year
1
Growths faster than the competition
Cons
0
-

Performance of PerkinElmer Inc. vs. its peers

Security Change (%) 1w 1m 1y YTD 3y 5y
PerkinElmer Inc. -0.830% -2.419% 5.217% 32.967% 5.217% 84.733% 172.430%
Hologic Inc. 0.000% -2.381% 0.000% 25.510% 6.957% 77.746% 90.520%
Boston Scientific -0.890% 0.635% 6.793% -23.153% 2.818% 32.039% 83.310%
Thermo Fisher Scientific Inc. 0.660% -0.263% 11.027% 37.944% 9.656% 137.131% 233.453%

Comments

Buy PerkinElmer Inc.

Other discussions about PerkinElmer Inc. Stock

Trading PerkinElmer Inc.

Trading PerkinElmer Inc.

New thread Forum

News

PerkinElmer SARS-CoV-2 RT-PCR Assay Receives FDA EUA for Asymptomatic Testing: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24701/263px-PerkinElmer.svg.png
PerkinElmer SARS-CoV-2 RT-PCR Assay Receives FDA EUA for Asymptomatic Testing


PerkinElmer, Inc. (NYSE:PKI) announced today that its PerkinElmer® New Coronavirus Nucleic Acid Detection Kit received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration

PerkinElmer Updates Fourth Quarter Outlook; To Hold Earnings Call on Tuesday, February 2, 2021: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24701/263px-PerkinElmer.svg.png
PerkinElmer Updates Fourth Quarter Outlook; To Hold Earnings Call on Tuesday, February 2, 2021


PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that it anticipates reported and organic revenue growth of approximately 66% and 63%

PerkinElmer to Acquire Oxford Immunotec Global PLC: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24701/263px-PerkinElmer.svg.png
PerkinElmer to Acquire Oxford Immunotec Global PLC


PerkinElmer, Inc. (NYSE: PKI) (“PerkinElmer”) and Oxford Immunotec Global PLC (NASDAQ: OXFD) ("Oxford Immunotec" or the “Company”) are pleased to announce they have reached an agreement on terms

PerkinElmer to Present at J.P. Morgan Healthcare Conference: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24701/263px-PerkinElmer.svg.png
PerkinElmer to Present at J.P. Morgan Healthcare Conference


PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the annual J.P. Morgan Healthcare Conference on

PerkinElmer to Host Virtual Life Science Event: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24701/263px-PerkinElmer.svg.png
PerkinElmer to Host Virtual Life Science Event


PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will host a Virtual Life Science Event for the investment community on

PerkinElmer SARS-CoV-2 RT-PCR Assay Receives CE Mark for Saliva and Sample Pooling to Test Symptomatic and Asymptomatic Individuals: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24701/263px-PerkinElmer.svg.png
PerkinElmer SARS-CoV-2 RT-PCR Assay Receives CE Mark for Saliva and Sample Pooling to Test Symptomatic and Asymptomatic Individuals


PerkinElmer, Inc. (NYSE:PKI) announced today that its PerkinElmer® SARS-CoV-2 Real-time RT-PCR Assay received CE-IVD marking for the use of saliva as specimen type and the option to pool up to five

EUROIMMUN Launches Quantitative ELISA to Measure SARS-CoV-2 Antibodies Against Viral S1 Protein: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24701/263px-PerkinElmer.svg.png
EUROIMMUN Launches Quantitative ELISA to Measure SARS-CoV-2 Antibodies Against Viral S1 Protein


PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, announced today that EUROIMMUN, a PerkinElmer company, has launched the Anti-SARS-CoV-2 QuantiVacTM

PerkinElmer to Present at Wolfe Virtual Healthcare Conference: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24701/263px-PerkinElmer.svg.png
PerkinElmer to Present at Wolfe Virtual Healthcare Conference


PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the Wolfe Virtual Healthcare Conference on Thursday

PerkinElmer to Present at Stifel Virtual Healthcare Conference: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24701/263px-PerkinElmer.svg.png
PerkinElmer to Present at Stifel Virtual Healthcare Conference


PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the Stifel Virtual Healthcare Conference on Tuesday

PerkinElmer COVID-19 Test Kit Receives FDA Emergency Use Authorization for Sample Pooling: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24701/263px-PerkinElmer.svg.png
PerkinElmer COVID-19 Test Kit Receives FDA Emergency Use Authorization for Sample Pooling


PerkinElmer, Inc. (NYSE: PKI) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) to allow sample pooling with PerkinElmer® New Coronavirus

PerkinElmer Announces Financial Results for the Third Quarter of 2020: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24701/263px-PerkinElmer.svg.png
PerkinElmer Announces Financial Results for the Third Quarter of 2020


PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the third quarter ended October 4, 2020.



The Company reported

PerkinElmer Receives CE Mark for Multi-analyte Respiratory Panel Including COVID-19 : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24701/263px-PerkinElmer.svg.png
PerkinElmer Receives CE Mark for Multi-analyte Respiratory Panel Including COVID-19


PerkinElmer, Inc. (NYSE: PKI) announced today that its PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel has received clearance to be marketed as an in vitro diagnostic (IVD) device in more than 30

PerkinElmer Board Declares Quarterly Dividend: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24701/263px-PerkinElmer.svg.png
PerkinElmer Board Declares Quarterly Dividend


The Board of Directors of PerkinElmer, Inc. (NYSE: PKI), declared a regular quarterly dividend of $0.07 per share of common stock October 22, 2020. This dividend is payable on February 12, 2021 to

CORRECTING and REPLACING PerkinElmer Updates Third Quarter Outlook; To Hold Earnings Call on Wednesday, October 28, 2020


The table in the release was incorrect. The corrected table should read:



PerkinElmer, Inc:

PerkinElmer, Inc. and SubsidiariesRECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1)

PerkinElmer to Present at BofA Global Healthcare Conference 2020


PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the BofA Global Healthcare Conference 2020 on